Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Two-Part, Phase 1B Clinical Study of CMP-001 in Combination With Atezolizumab With and Without Radiation Therapy in Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)

NCT03438318 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT03438318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03438318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Two-Part, Phase 1B Clinical Study of CMP-001 in Combination With Atezolizumab With and Without Radiation Therapy in Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
March 15, 2018
Completion date
December 11, 2019
Enrollment
29 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer